基础医学与临床 ›› 2026, Vol. 46 ›› Issue (8): 1027-1035.doi: 10.16352/j.issn.1001-6325.2026.08.1027

• 研究论文 • 上一篇    下一篇

TLR7/8激动剂R848抑制Vδ2 γδ Treg的诱导及功能

再吐娜·热合木, 党光蕾, 张祥晋, 张建民, 何维, 陈慧*   

  1. 中国医学科学院北京协和医学院 基础医学研究所 免疫学系,北京 100005
  • 收稿日期:2026-04-02 修回日期:2026-04-28 发布日期:2026-07-22
  • 通讯作者: *chenhui_1980@126.com
  • 基金资助:
    中国医学科学院医学与健康科技创新工程科技攻关项目(2025-I2M-KJ-012);国家自然科学基金面上项目(32270915);常州西太湖细胞治疗前沿技术发展基金会项目(2024-P-013)

TLR7/8 agonist R848 inhibits the induction and function of Vδ2 γδ Treg

Zaituna REHEMU, DANG Guanglei, ZHANG Xiangjin, ZHANG Jianmin, HE Wei, CHEN Hui*   

  1. Department of Immunology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
  • Received:2026-04-02 Revised:2026-04-28 Published:2026-07-22
  • Contact: *chenhui_1980@126.com

摘要: 目的 探讨TLR7/8激动剂雷西莫特(R848)对转化生长因子β1(TGF-β1)诱导的γδ Treg产生及其免疫抑制功能的影响,并分析其相关分子机制。方法 用抗人γδ TCR抗体扩增外周血γδ T细胞;同时,加入不同浓度TGF-β1,流式细胞术检测转录因子叉头框P3(FoxP3)的表达,确定诱导γδ Treg的条件;分别进行Vδ1和Vδ2 γδ Treg诱导,流式细胞术检测R848对FoxP3+ γδ Treg比例的影响;磁珠分选诱导的Vδ1和Vδ2 γδ T细胞,用CFSE实验检测R848对γδ Treg抑制CD4+ T细胞增殖作用的影响,并用流式细胞术、Western blot和酶联免疫吸附试验(ELISA)检测γδ Treg穿孔素、颗粒酶B和颗粒酶K的表达以及TGF-β1的分泌;用RNA-seq探究R848发挥功能的相关分子机制,并对关键差异表达蛋白进行Western blot验证。结果 3 ng/mL TGF-β1能在体外成功诱导γδ T细胞表达FoxP3;R848对TGF-β1诱导的FoxP3+ Vδ1 γδ Treg的产生没有影响,但能显著降低FoxP3+ Vδ2 γδ Treg的比例;R848处理能逆转Vδ2 γδ Treg对CD4+ T细胞的增殖抑制作用,而对Vδ1 γδ Treg无效;R848能部分逆转Vδ2 γδ Treg的抑制功能,促进其表达颗粒酶B;同时,显著降低其自身TGF-β1的分泌水平;RNA-seq分析及Western blot验证结果显示,R848通过抑制Janus酪氨酸激酶(JAK)/信号转导和转录激活因子(STAT)通路的关键负调控蛋白SOCS1和CISH的表达以及抑制STAT3的磷酸化,实现对Vδ2 γδ Treg功能的逆转。结论 TLR7/8激动剂R848能部分逆转TGF-β1诱导的Vδ2 γδ Treg产生及其抑制功能,为γδ T细胞联合R848协同增效的肿瘤免疫治疗策略提供了实验支持。

关键词: γδ T细胞, Toll样受体激动剂, R848, 转化生长因子β1

Abstract: Objective To investigate the effects of TLR7/8 agonist Resiquimod (R848) on the generation and immunosuppressive function of γδ Treg induced by TGF-β1, and explore the underlying molecular mechanisms. Methods γδ T cells were expanded with anti-human γδ TCR antibodies in the presence of different concentrations of TGF-β1, and the expression of transcription factor forkhead box protein P3 (FoxP3) in γδ T cells was subsequently analyzed by flow cytometry. Then Vδ1 and Vδ2 γδ T cells were amplified by anti-human Vδ1 TCR anti- body and anti-human γδ TCR antibody respectively, and R848 was added to the induction system to examine its effect on the proportion of FoxP3+γδ Treg. Induced Vδ1 and Vδ2 γδ T cells were isolated by magnetic-activated cell sorting, and the effect of R848 on their suppressive function against CD4+ T cell proliferation was assessed by a CFSE dilution assay. Flow cytometry was used to detect the expression of perforin and granzyme B. Western blot was performed to measure the expression level of granzyme K. ELISA was used to determine the concentration of TGF-β1 in the supernatant, and RNA sequencing was performed to identify differentially expressed genes after R848 treatment with validation using Western blot. Results 3 ng/mL TGF-β1 significantly increased the expression of FoxP3 in γδ T cells. R848 had no significant effect on the generation of TGF-β1-induced FoxP3+ Vδ1 γδ Treg, but significantly reduced the proportion of FoxP3+ Vδ2 γδ Treg. R848 treatment reversed the suppressive effect of Vδ2 γδ Treg on CD4+ T cell proliferation, whereas no such effect was observed in Vδ1 γδ Treg. R848 partially reversed the suppressive function of Vδ2 γδ Treg, promoted granzyme B expression, and significantly decreased their secretion of TGF-β1.RNA-seq analysis and Western blot validation demonstrated that R848 reversed the suppressive function of Vδ2 γδ Treg by downregulating the expression of SOCS1 and CISH, two key negative regulators of the JAK/STAT signaling pathway and inhibiting STAT3 phosphorylation. Conclusions The TLR7/8 agonist R848 reverses the generation and suppressive function of TGF-β1-induced Vδ2 γδ Treg. These findings provide experimental support for the development of a combinational immunotherapeutic strategy involving γδ T cells and R848.

Key words: γδ T cells, TLR agonist, R848, TGF-β1

中图分类号: